Abstract

Cabergoline is a potent, D2-selective new dopamine agonist with a half- life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better tolerated than bromocriptine, compliance may be improved, and costs are comparable. In cases of bromocriptine failure, unusually high starting doses of cabergoline may be necessary. Cabergoline may eventually replace bromocriptine as the drug of choice in prolactinomas.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalNeuro-Ophthalmology
Volume22
Issue number1
DOIs
StatePublished - 1999

Keywords

  • Bromocriptine resistance
  • Cabergoline
  • Metastatic prolactinomas
  • Prolactinomas

ASJC Scopus subject areas

  • Clinical Neurology
  • Ophthalmology

Fingerprint Dive into the research topics of 'Cabergoline in prolactinomas'. Together they form a unique fingerprint.

Cite this